AIM ImmunoTech公司公布了其针对胰腺癌治疗的二期临床研究的中期积极进展。该研究旨在评估其药物Ampligen®（rintatolimod）与阿斯利康的Imfinzi®（durvalumab）联合疗法的效果。
此次公布的中期数据展现了令人鼓舞的临床发展态势。研究探索了这种联合用药方案在治疗胰腺癌患者中的潜力。胰腺癌作为一种侵袭性强、治疗选择有限的恶性肿瘤，新的有效疗法备受期待。
公司报告的中期进展为后续研究提供了支持。Ampligen®作为一种免疫调节剂，与Imfinzi®这一免疫检查点抑制剂的结合，代表了一种创新的治疗策略。该策略旨在激活患者自身的免疫系统来对抗癌细胞。
这一积极进展标志着公司在肿瘤免疫治疗领域迈出了重要一步。后续的完整临床数据将为进一步评估该联合疗法的安全性与有效性提供关键依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.